CADROFLOXACIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C19H20F3N3O4
Molecular Weight	411.375
Optical Activity	( - )
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@H]1CN(CCN1)C2=C(OC(F)F)C3=C(C=C2F)C(=O)C(=CN3C4CC4)C(O)=O

InChI

InChIKey=QBDBUKJBJJWZMG-VIFPVBQESA-N

InChI=1S/C19H20F3N3O4/c1-9-7-24(5-4-23-9)15-13(20)6-11-14(17(15)29-19(21)22)25(10-2-3-10)8-12(16(11)26)18(27)28/h6,8-10,19,23H,2-5,7H2,1H3,(H,27,28)/t9-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C19H20F3N3O4
Molecular Weight	411.375
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://newdrugapprovals.org/2016/05/09/cadrofloxacin/
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/8723467

Cadrofloxacin hydrochloride was studied for the treatment of bacterial infections. The compound was originally developed by UBE and Daiichi Sankyo. However, this study was discontinued. The compound currently was developed by Hengrui. Cadrofloxacin showed potent bactericidal activity against S. aureus, Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Staphylococcus aureus growth 27 Target ID: Staphylococcus aureus growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/9371375	Inhibitor 8504
Streptococcus pneumoniae growth 20 Target ID: Streptococcus pneumoniae growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/9371375	Inhibitor 8504
Haemophilus influenzae growth 4 Target ID: Haemophilus influenzae growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/9371375	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Respiratory infections 12 Sources: http://www.ncbi.nlm.nih.gov/pubmed/9371375	Curative		Basic research	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
[In vitro anti-MAC activities of new quinolones in focus (1)].	1996-09	8999136
[Determination of antimycobacterial activities of fluoroquinolones against clinical isolates of Mycobacterium tuberculosis: comparative determination with egg-based Ogawa and agar-based Middlebrook 7H10 media].	1996-08	8831190
Antimicrobial activity of CS-940, a new trifluorinated quinolone.	1995-10	8619590

Patents

Sample Use Guides

In Vivo Use Guide

400 mg cadrofloxacin hydrochloride once a day for 7 d by intravenous drip infusion

Route of Administration: Intravenous

In Vitro Use Guide

Cadrofloxacin (CS-940) was active against methicillin-resistant S. aureus with MIC90 of 16 ug/ml.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 08:56:58 GMT 2025` Edited by `admin` on `Wed Apr 02 08:56:58 GMT 2025`
Record UNII	1YOQ7J9ACY
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

cadrofloxacin [INN]

Preferred Name

English

CADROFLOXACIN

Official Name

English

(-)-1-CYCLOPROPYL-8-(DIFLUOROMETHOXY)-6-FLUORO-1,4-DIHYDRO-7-((S)-3-METHYL-1-PIPERAZINYL)-4-OXO-3-QUINOLINECARBOXYLIC ACID

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C795